DB:GKO

Stock Analysis Report

Executive Summary

GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States.


Snowflake Analysis

Excellent balance sheet and fair value.

Share Price & News

How has GlycoMimetics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: GKO's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-3.7%

GKO

-4.3%

DE Biotechs

-4.7%

DE Market


1 Year Return

-65.9%

GKO

5.5%

DE Biotechs

8.3%

DE Market

Return vs Industry: GKO underperformed the German Biotechs industry which returned 5.5% over the past year.

Return vs Market: GKO underperformed the German Market which returned 8.3% over the past year.


Shareholder returns

GKOIndustryMarket
7 Day-3.7%-4.3%-4.7%
30 Day-14.6%-6.7%-4.0%
90 Day-27.0%0.4%-1.4%
1 Year-65.9%-65.9%5.8%5.5%11.7%8.3%
3 Year-38.7%-38.7%40.9%39.4%11.4%1.6%
5 Year-51.4%-51.4%10.9%8.6%15.1%-0.7%

Price Volatility Vs. Market

How volatile is GlycoMimetics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is GlycoMimetics undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: GKO (€3.56) is trading below our estimate of fair value (€23.12)

Significantly Below Fair Value: GKO is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: GKO is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: GKO is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate GKO's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: GKO is good value based on its PB Ratio (1x) compared to the DE Biotechs industry average (3.5x).


Next Steps

Future Growth

How is GlycoMimetics forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

41.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: GKO is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: GKO is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: GKO is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if GKO's revenue is forecast to grow faster than the German market.

High Growth Revenue: Insufficient data to determine if GKO's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if GKO's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has GlycoMimetics performed over the past 5 years?

-32.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: GKO is currently unprofitable.

Growing Profit Margin: GKO is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: GKO is unprofitable, and losses have increased over the past 5 years at a rate of -32.3% per year.

Accelerating Growth: Unable to compare GKO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: GKO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).


Return on Equity

High ROE: GKO has a negative Return on Equity (-34.16%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is GlycoMimetics's financial position?


Financial Position Analysis

Short Term Liabilities: GKO's short term assets ($174.8M) exceed its short term liabilities ($10.4M).

Long Term Liabilities: GKO's short term assets ($174.8M) exceed its long term liabilities ($2.9M).


Debt to Equity History and Analysis

Debt Level: GKO is debt free.

Reducing Debt: GKO had no debt 5 years ago.


Balance Sheet

Inventory Level: GKO has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if GKO's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: GKO has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if GKO has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is GlycoMimetics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage1.0%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate GKO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate GKO's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if GKO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if GKO's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of GKO's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

7.0yrs

Average management tenure


CEO

Rachel King (60yo)

17.1yrs

Tenure

US$3,185,153

Compensation

Mrs. Rachel K. King co-founded Glycomimetics, Inc. in 2003 and has been its Chief Executive Officer and its President since 2003. She has been a Director of Novavax, Inc. since November 1, 2018. Mrs. King  ...


CEO Compensation Analysis

Compensation vs Market: Rachel's total compensation ($USD3.19M) is above average for companies of similar size in the German market ($USD626.29K).

Compensation vs Earnings: Rachel's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Rachel King
President17.1yrsUS$3.19m1.12% $1.8m
Brian Hahn
Senior VP8.1yrsUS$1.40mno data
John Magnani
Senior VP of Research & Chief Scientific Officer17.1yrsUS$1.56m0.68% $1.1m
Helen Thackray
Senior VP of Clinical Development & Chief Medical Officer 14.1yrsUS$1.60m0.34% $542.3k
Stephanie Irish
Vice President of Accounting1.1yrsno datano data
Henry Flanner
Vice President of Technical Operations3.6yrsno datano data
Christian Dinneen-Long
VP, Corporate Counsel & Corporate Secretary0.8yrsno datano data
Armand Girard
Senior Vice President of Strategy and Corporate Development5.8yrsno datano data

7.0yrs

Average Tenure

50.5yo

Average Age

Experienced Management: GKO's management team is seasoned and experienced (7 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Rachel King
President17.1yrsUS$3.19m1.12% $1.8m
John Magnani
Senior VP of Research & Chief Scientific Officer17.1yrsUS$1.56m0.68% $1.1m
Daniel Junius
Independent Director3.9yrsUS$192.43k0.042% $65.7k
Timothy Pearson
Chairman of the Board0.8yrsUS$196.36kno data
Scott Koenig
Independent Director2.9yrsUS$180.29kno data
Scott Jackson
Director1.3yrsUS$172.11kno data
Patricia S. Andrews
Independent Director2.7yrsUS$183.79kno data
Mark Goldberg
Independent Director5.6yrsUS$189.79k0.027% $42.0k

3.4yrs

Average Tenure

62.5yo

Average Age

Experienced Board: GKO's board of directors are considered experienced (3.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 11.4%.


Top Shareholders

Company Information

GlycoMimetics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: GlycoMimetics, Inc.
  • Ticker: GKO
  • Exchange: DB
  • Founded: 2003
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$172.139m
  • Listing Market Cap: US$158.230m
  • Shares outstanding: 43.36m
  • Website: https://www.glycomimetics.com

Number of Employees


Location

  • GlycoMimetics, Inc.
  • 9708 Medical Center Drive
  • Rockville
  • Maryland
  • 20850
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
GLYCNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDJan 2014
GKODB (Deutsche Boerse AG)YesCommon StockDEEURJan 2014

Biography

GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company’s advanced drug candidate, rivipansel, is a pan-selectin antagonist, which is developed for the treatment of vaso-occlusive crisis in sickle cell disease and is in a Phase III clinical trial, conducted by its strategic collaboration with Pfizer Inc. It is also developing uproleselan, an E-selectin antagonist that is evaluated in a Phase I/II clinical trial as a potential treatment for acute myeloid leukemia (AML), as well as Phase III trial to treat relapsed/refractory AML. In addition, the company offers GMI-1359 that has completed Phase I clinical trial to target E-selectin and a chemokine receptor for various tumor types. Further, it is developing various other programs, including GMI-1687, an antagonist of E-selectin; and Galectin-3, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute. GlycoMimetics, Inc. was founded in 2003 and is headquartered in Rockville, Maryland. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/25 22:32
End of Day Share Price2020/02/25 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.